{{Rsnum
|rsid=11083241
|Gene=CDH2
|Chromosome=18
|position=27971997
|Orientation=plus
|GMAF=0.4789
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=CDH2
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 37.5 | 46.4 | 16.1
| HCB | 24.1 | 54.0 | 21.9
| JPT | 26.5 | 50.4 | 23.0
| YRI | 6.1 | 40.8 | 53.1
| ASW | 10.5 | 47.4 | 42.1
| CHB | 24.1 | 54.0 | 21.9
| CHD | 24.8 | 51.4 | 23.9
| GIH | 24.8 | 46.5 | 28.7
| LWK | 9.1 | 40.9 | 50.0
| MEX | 15.5 | 56.9 | 27.6
| MKK | 15.4 | 44.9 | 39.7
| TSI | 24.8 | 60.4 | 14.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs11083241
|Name_s=
|Gene_s=CDH2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00004. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109338
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11083241
|overall_frequency_n=63
|overall_frequency_d=128
|overall_frequency=0.492188
|n_genomes=41
|n_genomes_annotated=0
|n_haplomes=55
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}